May 17, 2021 A de-escalation antiplatelet strategy of switching from the more-potent ticagrelor (Brilinta; AstraZeneca) to clopidogrel at 1 month after PCI for acute MI is superior to continuing on ticagrelor and aspirin in terms of net clinical benefit, according to the TALOS-AMI trial. “This study was conducted only in South Korea. However, although the prevalence of the CYP2C19 loss-of-function allele is significantly higher in Koreans than in other ethnic groups, this study showed the clinical safety of switching in this population, suggesting the potential of applying this de-escalation strategy to other ethnic groups,” said Kiyuk Chang, MD, PhD (The Catholic University of Korea, Seoul, Republic of Korea), who presented the findings in a late-breaking clinical trial session yesterday at the American College of Cardiology 2021 Scientific Session.